FR2693876A1 - Micro-nutrient compsn. to combat the effects of stress - contains B vitamin(s), octacosanol, calcium, magnesium, chromium and zinc and opt. other micro-nutrients - Google Patents
Micro-nutrient compsn. to combat the effects of stress - contains B vitamin(s), octacosanol, calcium, magnesium, chromium and zinc and opt. other micro-nutrients Download PDFInfo
- Publication number
- FR2693876A1 FR2693876A1 FR9209161A FR9209161A FR2693876A1 FR 2693876 A1 FR2693876 A1 FR 2693876A1 FR 9209161 A FR9209161 A FR 9209161A FR 9209161 A FR9209161 A FR 9209161A FR 2693876 A1 FR2693876 A1 FR 2693876A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- deficiencies
- magnesium
- octacosanol
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 239000011785 micronutrient Substances 0.000 title claims abstract description 19
- 235000013369 micronutrients Nutrition 0.000 title claims abstract description 19
- 239000011777 magnesium Substances 0.000 title claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 11
- 229960002666 1-octacosanol Drugs 0.000 title claims abstract description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 239000011575 calcium Substances 0.000 title claims abstract description 10
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 10
- 229910052804 chromium Inorganic materials 0.000 title claims abstract description 10
- 239000011651 chromium Substances 0.000 title claims abstract description 10
- 239000011701 zinc Substances 0.000 title claims abstract description 10
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 9
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 title claims abstract description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 title abstract description 9
- 235000019156 vitamin B Nutrition 0.000 title description 2
- 239000011720 vitamin B Substances 0.000 title description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000007812 deficiency Effects 0.000 claims abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940088594 vitamin Drugs 0.000 claims abstract description 14
- 229930003231 vitamin Natural products 0.000 claims abstract description 14
- 235000013343 vitamin Nutrition 0.000 claims abstract description 14
- 239000011782 vitamin Substances 0.000 claims abstract description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 14
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 229910052742 iron Inorganic materials 0.000 claims abstract description 7
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 6
- 229910052802 copper Inorganic materials 0.000 claims abstract description 6
- 239000010949 copper Substances 0.000 claims abstract description 6
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 6
- 239000011733 molybdenum Substances 0.000 claims abstract description 6
- 239000011574 phosphorus Substances 0.000 claims abstract description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 6
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 6
- 239000011719 vitamin A Substances 0.000 claims abstract description 6
- 229940045997 vitamin a Drugs 0.000 claims abstract description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011669 selenium Substances 0.000 claims abstract description 5
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 5
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 5
- 230000004382 visual function Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 7
- 229930003571 Vitamin B5 Natural products 0.000 claims description 7
- 229960002079 calcium pantothenate Drugs 0.000 claims description 7
- 239000011675 vitamin B5 Substances 0.000 claims description 7
- 235000009492 vitamin B5 Nutrition 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 229930003537 Vitamin B3 Natural products 0.000 claims description 6
- 229930003761 Vitamin B9 Natural products 0.000 claims description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 6
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019160 vitamin B3 Nutrition 0.000 claims description 6
- 239000011708 vitamin B3 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000021468 vitamin B8 Nutrition 0.000 claims description 6
- 235000019159 vitamin B9 Nutrition 0.000 claims description 6
- 239000011727 vitamin B9 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 claims description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000036541 health Effects 0.000 abstract description 4
- 235000020802 micronutrient deficiency Nutrition 0.000 abstract description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000037213 diet Effects 0.000 abstract description 3
- 229910052748 manganese Inorganic materials 0.000 abstract description 3
- 239000011572 manganese Substances 0.000 abstract description 3
- 235000013734 beta-carotene Nutrition 0.000 abstract description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 abstract description 2
- 239000011648 beta-carotene Substances 0.000 abstract description 2
- 229960002747 betacarotene Drugs 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 abstract 1
- 206010001584 alcohol abuse Diseases 0.000 abstract 1
- 208000025746 alcohol use disease Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 235000001705 insufficient nutrition Nutrition 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 235000018648 unbalanced nutrition Nutrition 0.000 abstract 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 206010001488 Aggression Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
COMPLEXENT NUTRITIF A BASE DE NICRONUTRIMENTS
L'invention concerne un complément nutritif à base de micronutriments.NICRONUTRIENT-BASED NUTRITION COMPLEX
The invention relates to a nutritional supplement based on micronutrients.
Les progrès de la biochimie moléculaire permettent de mieux cerner le rôle prépondérant de métabolites tels que les vitamines, les oligo-éléments, les acides aminés, les enzymes, coenzymes, etc. dans le métabolisme cellulaire. Advances in molecular biochemistry allow us to better understand the preponderant role of metabolites such as vitamins, trace elements, amino acids, enzymes, coenzymes, etc. in cell metabolism.
Les micronutriments, dont les besoins sont quantitativement très faibles, sont cependant des nutriments indispensables. Ils comprennent d'une part, des composés minéraux, d'autre part des composés organiques (vitamines) dont l'homme est incapable d'effectuer la synthèse. En raison de leur participation à des activités métaboliques très diverses, notamment enzymatiques, ce sont des facteurs d'utilisation métabolique, essentiels et non pas accessoires. Micronutrients, whose needs are quantitatively very low, are however essential nutrients. They include on the one hand, mineral compounds, on the other hand organic compounds (vitamins) which humans are unable to synthesize. Because of their participation in very diverse metabolic activities, notably enzymatic, they are factors of metabolic use, essential and not incidental.
Les carences en ces micronutriments, liées à une alimentation insuffisante ou déséquilibrée, affectent de façon plus ou moins invalidante toutes les classes de population. Deficiencies in these micronutrients, linked to an insufficient or unbalanced diet, more or less disabling affect all classes of the population.
Par ailleurs, l'évolution des régimes alimentaires, la pratique abusive d'alcool, de tabac, de certains médicaments, associés à la civilisation urbaine, augmentent les besoins en certains micronutriments. In addition, the evolution of diets, the abusive practice of alcohol, tobacco, certain drugs, associated with urban civilization, increase the needs for certain micronutrients.
La satisfaction imparfaite des besoins nutritionnels se traduit rapidement par des altérations de la santé et des activités de l'adulte ou de l'enfant et par des dysfonctionnements du développement ; en fait la malnutrition affecte plus que toute autre maladie la santé de l'homme. The imperfect satisfaction of nutritional needs quickly results in alterations in the health and activities of adults or children and in developmental dysfunctions; in fact malnutrition affects human health more than any other disease.
On connaît des complexes spécifiques, destinés à combler les déficiences mentionnées ci-dessus. Chacun peut y trouver le ou les micronutriments qui font défaut à l'apport nutritionnel conseillé. Specific complexes are known, intended to fill the deficiencies mentioned above. Everyone can find the micronutrient (s) that are lacking in the recommended nutritional intake.
Mais la malnutrition n'est pas la seule cause de ces altérations de la santé et un apport nutritionnel ne peut être vraiment efficace que si l'on tient compte d'un facteur déstabilisant de la société actuelle couramment appelé "le stress". But malnutrition is not the only cause of these alterations in health and nutritional intake can only be truly effective if one takes into account a destabilizing factor in current society commonly called "stress".
Que ce soit sous forme d'agression, de stimulation, de contrainte, de pression, de tension, d'émotion, le stress est omniprésent quotidiennement. Whether in the form of aggression, stimulation, constraint, pressure, tension, emotion, stress is omnipresent daily.
Or, le contrôle de la réaction de l'organisme à l'égard des agressions quotidiennes met en jeu des processus qui commencent à la molécule, aux enzymes, pour se poursuivre aux voies métaboliques, aux cellules, et atteindre tissus et systèmes, avant de s'exprimer par des symptômes pathologiques. However, controlling the body's reaction to daily aggressions involves processes that start at the molecule, at the enzymes, to continue in the metabolic pathways, in the cells, and reach tissues and systems, before express themselves through pathological symptoms.
En réaction à ces agressions, l'organisme s'adapte et accroit ses défenses contre les agressions en déclenchant le syndrome d'adaptation. Dans la mise en oeuvre des réactions le rôle de la cortico-surrénale, augmentant sa production d'adrénaline de corticoïdes est essentiel. Ce syndrome est déclenché par l'intermédiaire de l'hypophyse (hormone adreno-corticotrope). In response to these attacks, the body adapts and increases its defenses against the attacks by triggering the adaptation syndrome. In the implementation of reactions the role of the adrenal cortex, increasing its adrenaline production of corticosteroids is essential. This syndrome is triggered by the pituitary gland (adrenocorticotropic hormone).
Cette dépense supplémentaire d'énergie vient s'ajouter à la dépense métabolique d'entretien ou de repos (dépense basale) et conduit à une carence énergétique qui, si elle reste en l'état, peut provoquer de nombreux problèmes pathologiques. This additional expenditure of energy is added to the metabolic expenditure of maintenance or rest (basal expenditure) and leads to an energy deficiency which, if it remains in the state, can cause many pathological problems.
En d'autres termes, les mécanismes mis en jeu lors de la réaction de l'organisme aux agressions consomment, comme tous les processus physiologiques, des micronutriments que l'organisme soit ne synthétise pas, soit ne renouvelle jamais en quantité suffisante. In other words, the mechanisms involved in the reaction of the organism to aggressions consume, like all physiological processes, micronutrients that the organism either does not synthesize, or never renews in sufficient quantity.
Ces carences s'ajoutent aux carences nutritionnelles et il est donc indispensable d'en tenir compte dans tout traitement de ces dernières. C'est à cette condition seulement que les traitements auront leur pleine efficacité.These deficiencies are added to nutritional deficiencies and it is therefore essential to take them into account in any treatment of the latter. It is only on this condition that the treatments will have their full effectiveness.
En effet, le stress peut, s'il n'est pas traité par un complément nutritif spécifique, engendrer toute une série de dysfonctionnements des différents métabolismes de l'organisme
1) La répétition des stress entraîne par les carences en micronutriments qu'elle induit, un dysmétabolisme au niveau des glucides et lipides. Ce sont les facteurs fondamentaux de la distribution d'énergie.Indeed, stress can, if not treated with a specific nutritional supplement, cause a whole series of dysfunctions of the various metabolisms of the organism
1) The repetition of stresses leads by the micronutrient deficiencies which it induces, a dysmetabolism at the level of carbohydrates and lipids. These are the fundamental factors of energy distribution.
2) L'énergie étant le moteur de tous les mécanismes vitaux, les carences énergétiques entraînent à leur tour d'autres problèmes métaboliques. 2) Since energy is the engine of all vital mechanisms, energy deficiencies in turn lead to other metabolic problems.
3) Les facteurs carencés par l'effet du stress interviennent aussi dans l'autres métabolismes (notamment protéique) qui se trouvent à leur tour perturbés. 3) The factors deficient by the effect of stress also intervene in other metabolisms (notably protein) which are in turn disturbed.
4) En outre, le dérèglement du métabolisme lipidique favorise la formation des radicaux libres. 4) In addition, the dysregulation of lipid metabolism promotes the formation of free radicals.
5) La répétition du stress induit une plus grande sensibilité du système nerveux, qui se traduit par le déclenchement du syndrome d'adaptation pour des raisons de plus en plus bénignes. 5) The repetition of stress induces a greater sensitivity of the nervous system, which results in the triggering of the adaptation syndrome for more and more benign reasons.
C'est un véritable cercle vicieux qui s'instaure.It is a veritable vicious circle which is established.
L'objet de la présente invention est donc de proposer un complément nutritif dont la composition de base en micronutriments permet d'une part de pallier les inconvénients mentionnés ci-dessus et d'autre part, associée à d'autres micronutriments spécifiques permet le traitement de divers états carentiels. The object of the present invention is therefore to provide a nutritional supplement whose basic micronutrient composition makes it possible on the one hand to overcome the drawbacks mentioned above and on the other hand, associated with other specific micronutrients allows the treatment various deficiency states.
A cet effet, l'invention propose un complément nutritif dont la composition de base en micronutriments comprend au moins une vitamine du groupe B, de l'octacosanol, du calcium, du magnésium, du chrome et du zinc permettant de corriger les carences provoquées par le stress. To this end, the invention provides a nutritional supplement, the basic micronutrient composition of which comprises at least one vitamin from group B, octacosanol, calcium, magnesium, chromium and zinc, making it possible to correct the deficiencies caused by the stress.
La ou les vitamines du groupe B est (sont) notamment choisie(s) dans le groupe incluant la vitamine B1, la vitamine B2, la vitamine B3, la vitamine B5, la vitamine B6, la vitamine B8, la vitamine B9, seules ou en mélange entre-elles. The vitamin or vitamins of group B is (are) especially chosen from the group including vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B8, vitamin B9, alone or mixed together.
Selon d'autres caractéristiques de l'invention, prises seules ou en combinaison, le complément nutritif comprend en outre de la vitamine C, de la vitamine E, du fer, du cuivre, du manganèse, du molybdène, de la vitamine A sous sa forme vitamère S-carotène, du phosphore, du sélénium, de la superoxyde dismutase-1. According to other characteristics of the invention, taken alone or in combination, the nutritional supplement also comprises vitamin C, vitamin E, iron, copper, manganese, molybdenum, vitamin A in its vitamin form S-carotene, phosphorus, selenium, superoxide dismutase-1.
D'autres caractéristiques et avantages de l'invention apparaîtront clairement à la lecture de la description détaillée et des exemples qui suivent. Other characteristics and advantages of the invention will appear clearly on reading the detailed description and the examples which follow.
Le complément nutritif selon l'invention possède une composition de base en micrunut?iments comprenant au moins une vitamine du groupe B, de l'octacosanol, du calcium, du magnésium, du chrome, du zinc et permet de corriger les carences en micronutriments provoquées par le stress. The nutritional supplement according to the invention has a basic composition in micrunut? Iments comprising at least one vitamin of group B, octacosanol, calcium, magnesium, chromium, zinc and makes it possible to correct the deficiencies in micronutrients caused by stress.
La ou les vitamine(s) du groupe B est (sont) choisie(s) dans le groupe incluant la vitamine BI, la vitamine B2, la vitamine
B3, la vitamine B5, la vitamine B6, la vitamine B8, la vitamine B9, seules ou en mélange entre-elles.Vitamin (s) from group B is (are) chosen from the group including vitamin BI, vitamin B2, vitamin
B3, vitamin B5, vitamin B6, vitamin B8, vitamin B9, alone or as a mixture between them.
Ces carences en micronutriments sont dues à la réaction de l'organisme aux agressions extérieures dont la mise en oeuvre tant au niveau végétatif, tissulaire qu'endocrinien consomme un surcroît de micronutriments provoquant un dysfonctionnement des différents métabolismes de l'organisme. These micronutrient deficiencies are due to the body's reaction to external aggressions, the implementation of which at the vegetative, tissue and endocrine level consumes an excess of micronutrients causing dysfunction of the various metabolisms of the organism.
Ces micronutriments sont essentiellement
- La vitamine B5 et la vitamine C qui interviennent dans la synthèse de l'adrénaline.These micronutrients are essentially
- Vitamin B5 and vitamin C which are involved in the synthesis of adrenaline.
- Les vitamines du groupe B qui jouent un rôle dans le métabolisme des lipides. l'organisme carencé perd la faculté d'associer les protéines et les lipides, ce qui limite la possibilité de transporter ces derniers, de les stocker ou de les transformer en énergie. - Group B vitamins which play a role in lipid metabolism. the deficient organism loses the ability to associate proteins and lipids, which limits the possibility of transporting these, storing them or transforming them into energy.
- Le chrome qui occupe une place importante dans le métabolisme des sucres, des lipides et dans la disponibilité du magnésium. - Chromium which occupies an important place in the metabolism of sugars, lipids and in the availability of magnesium.
- Le zinc qui participe à l'activité biologique d'un très grand nombre d'enzymes. - Zinc which participates in the biological activity of a very large number of enzymes.
- Le calcium qui exerce une activité importante au niveau du système nerveux. Son métabolisme est perturbé, par l'excès de corticoïdes secrétés par la cortico-surrénale. - Calcium which exerts an important activity in the nervous system. Its metabolism is disturbed by the excess of corticosteroids secreted by the adrenal cortex.
- Le magnésium et l'octacosanol qui participent au maintien de l'équilibre nerveux et endocrinien tout en exerçant un effet sur le tonus musculaire. Cette double action est d'une grande efficacité pour induire une meilleure résistance au stress. - Magnesium and octacosanol which participate in maintaining the nervous and endocrine balance while exerting an effect on muscle tone. This double action is very effective in inducing better resistance to stress.
Plus particulièrement, le complément nutritif selon l'invention comprend par dose unitaire, 0,10 à 3 mg de vitamine B1 0,10 à 2 mg de vitamine B2 , 1 à 15 mg de vitamine B3 , 1 à 15 mg de vitamine B5 , 0,2 à 3 mg de vitamine B6 , 10 à 250 ug de vitamine B8
10 à 300 ug de vitamine B9 , 1 à 10 mg d'octacosanol , 50 mg à 1 g de calcium, 20 à 400 mg de magnésium, 10 à 200 pg de chrome, 1 à 20 mg de zinc.More particularly, the nutritional supplement according to the invention comprises, per unit dose, 0.10 to 3 mg of vitamin B1 0.10 to 2 mg of vitamin B2, 1 to 15 mg of vitamin B3, 1 to 15 mg of vitamin B5, 0.2 to 3 mg of vitamin B6, 10 to 250 ug of vitamin B8
10 to 300 ug of vitamin B9, 1 to 10 mg of octacosanol, 50 mg to 1 g of calcium, 20 to 400 mg of magnesium, 10 to 200 pg of chromium, 1 to 20 mg of zinc.
Cette composition de base du complément nutritif selon l'invention est destiné soit à être utilisée seule pour le traitement spécifique du stress soit à être associée à d'autres compositions. This basic composition of the nutritional supplement according to the invention is intended either to be used alone for the specific treatment of stress or to be combined with other compositions.
Le complément nutritif de la présente invention peut comprendre en outre de la vitamine C, de la vitamine E, du fer, du cuivre, du manganèse, du molybdène permettant en outre de corriger les carences de performances physiques et intellectuelles. The nutritional supplement of the present invention can also comprise vitamin C, vitamin E, iron, copper, manganese, molybdenum which also makes it possible to correct deficiencies in physical and intellectual performance.
La vitamine C agit comme facteurs antistress permettant à l'organisme de s'adapter plus facilement aux circonstances extérieures et est le plus puissant facilitateur connu de l'absorption du fer. Vitamin C acts as anti-stress factors allowing the body to adapt more easily to external circumstances and is the most powerful known facilitator of iron absorption.
La vitamine E protège contre l'oxydation des acides gras insaturés de l'organisme. Vitamin E protects against the oxidation of unsaturated fatty acids in the body.
Le fer joue un rôle fondamental dans le transport de l'oxygène et les mécanismes d'oxydo-réduction à l'intérieur de l'organisme. Iron plays a fundamental role in the transport of oxygen and redox mechanisms inside the body.
Le cuivre, le manganèse et le molybdène entrent dans la constitution de nombreux enzymes, notamment les superoxydesdismutases, facteurs d'élimination des radicaux libres. Copper, manganese and molybdenum are used in the constitution of many enzymes, in particular the superoxydesdismutases, factors of elimination of free radicals.
Selon l'invention, le complément nutritif peut comprendre en outre de la vitamine A sous sa forme vitamère S- carotène et du phosphore permettant en outre de corriger les carences des fonctions visuelles. According to the invention, the nutritional supplement can also comprise vitamin A in its vitamin S-carotene form and phosphorus which also makes it possible to correct deficiencies in visual functions.
La vitamine A est un constituant du pourpre rétinien. Vitamin A is a constituent of retinal purple.
Elle intervient également dans la vision diurne autant que dans la vision nocturne.It is also involved in daytime vision as much as in night vision.
Le phosphore est un nutriment qui joue un rôle fondamental au niveau du système nerveux. Phosphorus is a nutrient that plays a fundamental role in the nervous system.
Enfin, le complément nutritif de la présente invention peut comprendre en outre de la vitamine E, du sélénium et de la superoxyde dismutase -1 permettant en outre de neutraliser les radicaux libres générés par la peroxydation des acides gras insaturés de l'organisme. Finally, the nutritive supplement of the present invention can also comprise vitamin E, selenium and superoxide dismutase -1 making it possible moreover to neutralize the free radicals generated by the peroxidation of the unsaturated fatty acids of the organism.
Le rôle de la vitamine E a été explicité ci-dessus. Le sélénium, quant à lui, est un constituant, à l'état de sélénosystéine, de la peroxydase du glutathion, protéine enzymatique dont l'activité assure la protection des érythrocytes contre l'eau oxygénée (peroxyde d'hydrogène). The role of vitamin E has been explained above. Selenium, for its part, is a constituent, in the selenosysteine state, of peroxidase of glutathione, an enzymatic protein whose activity ensures the protection of erythrocytes against hydrogen peroxide (hydrogen peroxide).
A titre d'exemples non limitatifs on peut mentionner les compositions par capsule ou gélule suivantes
Composition de base
Vitamine B1 : 0,10 à 3 mg Octacosanol : 1 à 10 mg
Vitamine B2 : 0,10 à 2 mg Calcium : 50 mg à 1 g
Vitamine B3 : 1 à 15 mg Magnésium : 20 à 400 mg
Vitamine B5 : 1 à 15 mg Chrome : 10 à 200/g
Vitamine B6 : 0,2 à 3 mg Zinc : 1 à 20 mg
Vitamine B8 : 10 à 250 ug
Vitamine B9 : 10 à 300 pg
Cette composition de base est destinée plus particulièrement au traitement du stress.By way of nonlimiting examples, the following compositions per capsule or capsule may be mentioned
Basic composition
Vitamin B1: 0.10 to 3 mg Octacosanol: 1 to 10 mg
Vitamin B2: 0.10 to 2 mg Calcium: 50 mg to 1 g
Vitamin B3: 1 to 15 mg Magnesium: 20 to 400 mg
Vitamin B5: 1 to 15 mg Chromium: 10 to 200 / g
Vitamin B6: 0.2 to 3 mg Zinc: 1 to 20 mg
Vitamin B8: 10 to 250 ug
Vitamin B9: 10 to 300 pg
This basic composition is intended more particularly for the treatment of stress.
Cette composition de base associée à d'autres compositions en micronutriments permet de conjuguer leur effets sur l'organisme et d'accroître ainsi l'efficacité des traitements. This basic composition combined with other micronutrient compositions makes it possible to combine their effects on the organism and thus to increase the effectiveness of the treatments.
A titre d'exemples non limitatifs, on peut mentionner comme compositions associées
Composition associée 1
Vitamine C : 50 mg Manganèse : 3 mg
Vitamine E : 10 mg Molybdène : 200 pg
Fer : 10 mg
Cuivre : 2 mg
Composition associée 2
Vitamine A (ss-carotène) : 4000 U.I.As nonlimiting examples, there may be mentioned as associated compositions
Associated composition 1
Vitamin C: 50 mg Manganese: 3 mg
Vitamin E: 10 mg Molybdenum: 200 pg
Iron: 10 mg
Copper: 2 mg
Associated composition 2
Vitamin A (ss-carotene): 4000 IU
Phosphore : 600 mg. Phosphorus: 600 mg.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9209161A FR2693876A1 (en) | 1992-07-24 | 1992-07-24 | Micro-nutrient compsn. to combat the effects of stress - contains B vitamin(s), octacosanol, calcium, magnesium, chromium and zinc and opt. other micro-nutrients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9209161A FR2693876A1 (en) | 1992-07-24 | 1992-07-24 | Micro-nutrient compsn. to combat the effects of stress - contains B vitamin(s), octacosanol, calcium, magnesium, chromium and zinc and opt. other micro-nutrients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2693876A1 true FR2693876A1 (en) | 1994-01-28 |
Family
ID=9432235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9209161A Withdrawn FR2693876A1 (en) | 1992-07-24 | 1992-07-24 | Micro-nutrient compsn. to combat the effects of stress - contains B vitamin(s), octacosanol, calcium, magnesium, chromium and zinc and opt. other micro-nutrients |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2693876A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018618A3 (en) * | 1994-01-10 | 1995-10-05 | Abbott Laboratories | Enteral formula with ribo-nucleotides |
| FR2723682A1 (en) * | 1994-08-19 | 1996-02-23 | Boiron | Absorbable nutritional supplement for children and adolescents, to ensure daily micronutrient intake |
| EP0925790A1 (en) * | 1997-12-17 | 1999-06-30 | Kartar Dr. Lalvani | Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM) |
| WO1999043220A1 (en) * | 1998-02-25 | 1999-09-02 | Abbott Laboratories | Product and method to reduce stress induced immune suppression |
| EP1161884A1 (en) * | 2000-06-09 | 2001-12-12 | World Pharma Tech Ltd. | Proenergetic food supplement based on NADH, Octacosanol and Vitamin E |
| US6569445B2 (en) | 2000-12-05 | 2003-05-27 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity maintaining-agents |
| US6576253B2 (en) | 2000-12-05 | 2003-06-10 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
| WO2006014787A2 (en) * | 2004-07-27 | 2006-02-09 | Wyeth | Compositions containing policosanol and b vitamins and their pharmaceutical uses |
| WO2006014865A2 (en) * | 2004-07-27 | 2006-02-09 | Wyeth | Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses |
| EP1732605A2 (en) * | 2004-03-29 | 2006-12-20 | Wyeth | Multi-vitamin and mineral nutritional supplements |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6158536A (en) * | 1984-08-31 | 1986-03-25 | Nippon Oil & Fats Co Ltd | Nutrient composition |
| JPS61216659A (en) * | 1985-03-20 | 1986-09-26 | Nippon Oil & Fats Co Ltd | Nutritive food composition |
| JPS63219357A (en) * | 1987-03-07 | 1988-09-13 | Nippon Oil & Fats Co Ltd | Production of octacosanol-containing beverage |
| WO1991018593A1 (en) * | 1990-05-16 | 1991-12-12 | Board Of Regents, The University Of Texas System | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders |
| EP0488928A2 (en) * | 1990-11-30 | 1992-06-03 | Centro Nacional De Investigaciones Cientificas | Pharmaceutical formulations containing a mixture of higher primary aliphatic alcohols in the treatment of hypercholesterolaemia and hyperlypoproteinaemia type II and stimulation of sexual behavior in animals and humans |
-
1992
- 1992-07-24 FR FR9209161A patent/FR2693876A1/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6158536A (en) * | 1984-08-31 | 1986-03-25 | Nippon Oil & Fats Co Ltd | Nutrient composition |
| JPS61216659A (en) * | 1985-03-20 | 1986-09-26 | Nippon Oil & Fats Co Ltd | Nutritive food composition |
| JPS63219357A (en) * | 1987-03-07 | 1988-09-13 | Nippon Oil & Fats Co Ltd | Production of octacosanol-containing beverage |
| WO1991018593A1 (en) * | 1990-05-16 | 1991-12-12 | Board Of Regents, The University Of Texas System | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders |
| EP0488928A2 (en) * | 1990-11-30 | 1992-06-03 | Centro Nacional De Investigaciones Cientificas | Pharmaceutical formulations containing a mixture of higher primary aliphatic alcohols in the treatment of hypercholesterolaemia and hyperlypoproteinaemia type II and stimulation of sexual behavior in animals and humans |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPIL Section Ch, Week 8618, Derwent Publications Ltd., London, GB; Class D13, AN 86-117166(18) & JP-A-61 058 536 (NIPPON OILS & FATS ;SEVEN TECH) 25 Mars 1986 * |
| DATABASE WPIL Section Ch, Week 8842, Derwent Publications Ltd., London, GB; Class D13, AN 88-297717(42) & JP-A-63 219 357 (NIPPON OILS & FARS) 13 Septembre 1988 * |
| PATENT ABSTRACTS OF JAPAN vol. 11, no. 053 (C-404)19 Février 1987 & JP-A-61 216 659 ( NIPPON OIL & FATS ) 26 Septembre 1986 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018618A3 (en) * | 1994-01-10 | 1995-10-05 | Abbott Laboratories | Enteral formula with ribo-nucleotides |
| FR2723682A1 (en) * | 1994-08-19 | 1996-02-23 | Boiron | Absorbable nutritional supplement for children and adolescents, to ensure daily micronutrient intake |
| EP0925790A1 (en) * | 1997-12-17 | 1999-06-30 | Kartar Dr. Lalvani | Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM) |
| WO1999043220A1 (en) * | 1998-02-25 | 1999-09-02 | Abbott Laboratories | Product and method to reduce stress induced immune suppression |
| EP1161884A1 (en) * | 2000-06-09 | 2001-12-12 | World Pharma Tech Ltd. | Proenergetic food supplement based on NADH, Octacosanol and Vitamin E |
| US6576253B2 (en) | 2000-12-05 | 2003-06-10 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
| US6569445B2 (en) | 2000-12-05 | 2003-05-27 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity maintaining-agents |
| EP1732605A2 (en) * | 2004-03-29 | 2006-12-20 | Wyeth | Multi-vitamin and mineral nutritional supplements |
| EP1732605A4 (en) * | 2004-03-29 | 2009-05-27 | Wyeth Corp | Multi-vitamin and mineral nutritional supplements |
| WO2006014787A2 (en) * | 2004-07-27 | 2006-02-09 | Wyeth | Compositions containing policosanol and b vitamins and their pharmaceutical uses |
| WO2006014865A2 (en) * | 2004-07-27 | 2006-02-09 | Wyeth | Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses |
| WO2006014787A3 (en) * | 2004-07-27 | 2006-12-14 | Wyeth Corp | Compositions containing policosanol and b vitamins and their pharmaceutical uses |
| WO2006014865A3 (en) * | 2004-07-27 | 2007-01-04 | Wyeth Corp | Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parikh et al. | Calcium intake and adiposity | |
| Wallin et al. | Food and mood: relationship between food, serotonin and affective disorders | |
| FR2693876A1 (en) | Micro-nutrient compsn. to combat the effects of stress - contains B vitamin(s), octacosanol, calcium, magnesium, chromium and zinc and opt. other micro-nutrients | |
| FR2815227A1 (en) | Anti-stress composition designed to be administered using nutritional vehicle, comprises combination of linoleic and linolenic acid reducing stress hormones production, flavonoid-type component and sedative-type component | |
| WO1994001006A2 (en) | Composition for use as a food or food supplement | |
| Lucas et al. | Nutrition and mental development/Discussion | |
| GB2268871A (en) | Composition for use as a food or food supplement | |
| US20220023398A1 (en) | Compositions and methods for treating thyroid disease | |
| Hemat | Principles of orthomolecularism | |
| Ranawana et al. | Role of proteins in insulin secretion and glycemic control | |
| ITTO961031A1 (en) | AMINO ACID BASED COMPOSITIONS | |
| Reavley | The new encyclopedia of vitamins, minerals, supplements, & herbs: How they are best used to promote health and well being | |
| US20010041675A1 (en) | Satisfy composition and method of weight control | |
| CA2620313A1 (en) | Nutritional method for elderly people | |
| DE602004011275T2 (en) | Compositions and methods for the treatment of obesity | |
| FR2737849A1 (en) | Orally administered food supplement for adults of over forty | |
| Stawicki et al. | Current evidence from phase III clinical trials of selenium supplementation in critically Ill patients: why should we bother? | |
| FR2687548A1 (en) | Novel low-calory dietetic composition | |
| US20030064123A1 (en) | DHEA supplement for increasing women's libido | |
| Hafez et al. | Stress/aging: endocrine profiles/reproductive dysfunction in men | |
| De Groot et al. | Meeting nutrient and energy requirements in old age | |
| BONSALL et al. | 12 Nutrients, Neurotransmitters, and Brain Dysfunction | |
| CN1343454A (en) | Chinese-medicinal feed for layers | |
| Layer et al. | Pancreatic exocrine secretion | |
| US10702590B2 (en) | Compositions and methods for treating thyroid disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |